Compare Inovio Pharmaceuticals Inc (INO) vs Southern Copper Corp (SCCO) Price & Performance

INO trades at $1.09, down 5.63% today, with a bearish technical outlook and negative financial metrics including a net income margin of -130,000% and ROE of -409.87%. The company faces significant fundamental challenges with minimal revenue of $65,340 and substantial losses, though recent earnings have beaten expectations. Key near-term catalyst is the FDA decision on INO-3107 by October 30, 2026.

Despite analyst consensus favoring Buy ratings (58.83%) with a $2.75 price target, INO carries high risk due to persistent cash burn, negative profitability, and dependency on regulatory approvals. The stock offers speculative upside if INO-3107 gains approval but remains vulnerable to further dilution and operational setbacks.

Southern Copper (SCCO) trades at $198.66, down 0.95% on the day, with a bearish technical signal and mixed analyst sentiment. The company demonstrates strong fundamentals with revenue growth from $13.42B in 2025 to projected $15.8B in 2026, net income margins improving to 35.87%, and robust profitability metrics including 50.07% ROE. Recent earnings beats and a $10.2B Mexican project pipeline support long-term growth prospects, though the stock trades at premium valuations with P/E of 29.81 and P/S of 10.72.

SCCO presents a complex investment case with strong operational performance offset by valuation concerns. The upside potential lies in continued copper demand growth and project execution, while risks include premium valuation compression, commodity price volatility, and mixed Wall Street sentiment with only 10% buy ratings. Current price sits above the $165.60 consensus target, suggesting limited near-term upside despite fundamental strength.